INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $749,951 | -19.8% | 14,397 | -2.5% | 0.36% | -16.9% |
| Q2 2023 | $935,187 | +16.0% | 14,769 | -0.8% | 0.43% | -1.1% |
| Q1 2023 | $806,522 | -2.7% | 14,894 | -4.9% | 0.44% | -16.8% |
| Q4 2022 | $828,686 | +7.3% | 15,659 | -5.7% | 0.52% | +8.9% |
| Q3 2022 | $772,000 | -79.8% | 16,600 | -75.2% | 0.48% | -78.6% |
| Q2 2022 | $3,820,000 | -15.4% | 66,925 | -9.3% | 2.25% | +15.5% |
| Q1 2022 | $4,514,000 | +11.1% | 73,772 | -5.0% | 1.95% | +26.6% |
| Q4 2021 | $4,062,000 | – | 77,622 | – | 1.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |